WIP Warsaw IBD Point Profesor Kierkus | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients	Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder	Active, not recruiting	Phase 3	2026-09-25		NCT06408935
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease	Fistulizing Crohns Disease; Perianal Crohns Disease	Active, not recruiting	Phase 3	2026-09-25		NCT05347095
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Crohns Disease	Recruiting	Phase 3	2026-09-16		NCT06819878
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease	Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder	Active, not recruiting	Phase 2	2026-09-16		NCT05910528
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis	Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis	Recruiting	Phase 2	2026-07-08		NCT05287126
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder	Recruiting	Phase 3	2026-05-13		NCT05677971